CLN-049
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Phase 1/2Active; data presented at ASH
Key Facts
Indication
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Phase
Phase 1/2
Status
Active; data presented at ASH
Company
About Cullinan Therapeutics
Cullinan Therapeutics is a public, clinical-stage biotech company driving forward a deliberate pipeline of innovative therapies in autoimmune diseases and oncology. The company's strategy centers on rigorous scientific decision-making and strategic risk-taking to accelerate promising molecules. Key near-term catalysts include initial clinical data for CLN-978 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2025, and the completion of a rolling NDA submission for zipalertinib in EGFR exon 20 insertion non-small cell lung cancer (NSCLC).
View full company profileTherapeutic Areas
Other Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Actimab-A | Actinium Pharmaceuticals | Phase 2/3 |